Peptide Companion
Back to catalog
Peptide Companion
single
Growth Hormone
Vial: 10 mg

Sermorelin (10 mg Vial)

Sermorelin is a synthetic growth hormone–releasing hormone (GHRH) analog that stimulates endogenous pituitary GH secretion. Originally approved for pediatric growth hormone deficiency, it is studied for adult off‑label use to support physiologic GH output and IGF‑1 levels. This educational protocol presents a once‑daily subcutaneous approach administered at bedtime to align with natural nocturnal GH release.

Dose
0.2–0.5 mg per injection
Frequency
Once daily
Timing
Before bed
Duration
12+ weeks

GHRH analog. Gentle GH stimulation. Good for long-term protocols.

Dosing Schedule
WeekDaily Dose (µg)Units (per injection) (mL)
Weeks 1–2200 µg (0.2 mg)6 units (0.06 mL)
Weeks 3–4300 µg (0.3 mg)9 units (0.09 mL)
Weeks 5–6400 µg (0.4 mg)12 units (0.12 mL)
Weeks 7–8500 µg (0.5 mg)15 units (0.15 mL)
Supplies Needed
  • •Peptide Vials (Sermorelin, 10 mg each):
  • •Insulin Syringes (U‑100):
  • •Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • •Sharps Container: One puncture‑proof disposal container for used needles (sufficient for 56+ syringes).
References

  • PubMed

    Prakash & Goa (1999): Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (pediatric GHD; 30 µg/kg SC nightly; 6–12 month trials)

    View source

  • RxList

    Sermorelin Acetate Injection Monograph: dosing (0.2–0.3 mg SC qHS adult off‑label); reconstitution/storage/administration guidelines

    View source

  • PubMed

    Clinical studies: bedtime SC injection leverages natural nocturnal GH pulse; once‑daily nightly dosing yielded significant growth improvements in pediatric GHD over 6–12 months

    View source

  • Mayo Clinic

    Sermorelin (injection route) – Proper Use and Storage: refrigerate reconstituted solution at 2–8 °C (36–46 °F); do not freeze; use within recommended period

    View source

  • RxList

    Sermorelin Acetate Prescribing Information: adverse effects (injection‑site reactions ~17%; rare headache/flushing <1%); subclinical hypothyroidism ~6.5%; thyroid monitoring recommended

    View source

  • PubMed

    Sermorelin mechanism: stimulates endogenous pulsatile GH via GHRH receptors; preserves physiologic feedback loops (somatostatin/IGF‑1 negative feedback); reduces overdose risk vs. exogenous GH

    View source

  • Johns Hopkins Arthritis Center

    How to Give a Subcutaneous Injection: site selection (abdomen/thigh/arm); rotation guidelines; 45–90° angle; pinch technique; no aspiration; disposal in sharps container

    View source

  • CDC

    Vaccine administration: subcutaneous route technique (45–90° angle; site prep; no aspiration for SC injections)

    View source

  • PubMed

    Sermorelin dosing considerations: higher doses (up to 500 µg daily) used in research for greater IGF‑1 response in adults; aging/obesity associated with blunted GH release; cautious titration recommended

    View source

  • RxList

    Sermorelin treatment duration: pediatric studies 6–12 months daily therapy with sustained effect; some continued up to 36 months; adult off‑label cycles typically 3–6 months to evaluate efficacy

    View source

  • NCBI Bookshelf

    Best practices for parenteral injections: aseptic technique, preparation, administration guidelines

    View source

  • RxList

    Sermorelin safety profile: no serious acromegaly or hypoglycemia at recommended dosages; built‑in negative feedback prevents excessive GH/IGF‑1; FDA‑approved (as Geref) for decades with good safety record

    View source

Educational content adapted from peptidedosages.com. Not medical advice.